ALPMF News and Press, Astellas Pharma Inc From 05/29/20

Japan's Ministry of Health, Labor and Welfare approves Astellas Pharma's ( OTCPK:ALPMF ) Xtandi (enzalutamide) for the treatment of prostate cancer patients with distant metastases. More news on: Astellas Pharma Inc., Pfizer Inc., Astellas Pharma Inc., Healthcare stocks news, Read mo...

COVID-19 Pandemic Sorrento Therapeutics (SRNE), a San Diego-China biotech, reported that its anti-SARS-CoV-2 antibody, STI-1499, completely inhibited SARS-CoV-2 virus infection from interacting with the ACE2 receptor after four days of incubation (see story ). In preclinical studies, the mo...

Quick Take ORIC Pharmaceuticals ( ORIC ) intends to raise $75 million in an IPO of its common stock, per an amended S-1/A registration statement . The company is advancing a pipeline of drug candidates for the treatment of prostate cancer and solid tumors. ORIC is led by extremely capab...

Deals and Financings Qiming closed its seventh China-focused US dollar fund with $1.1 billion for early stage Healthcare and TMT investments. Currently, Qiming manages nine US dollar funds and five RMB funds with $5.3 billion of assets under management. Despite the COVID-19 pandemic, Qimin...

China's National Medical Products Administration has accepted for review Astellas Pharma's ( OTCPK:ALPMF ) marketing application seeking approval to use Xospata (gilteritinib) to treat adults with FLT3 mutation-positive acute myeloid leukemia (AML), a type of blood cancer with a poor progn...

Pharmaceutical stocks were initially expected to be largely immune to the COVID-19 economic downturn. Drugmakers, after all, generally produce products that are essential to daily life. However, the extreme social distancing that has become part and parcel of this unusual period has halted nume...

CytomX Therapeutics (NASDAQ: CTMX ) inks a collaboration agreement with Astellas Pharma ( OTCPK:ALPMF ) aimed at the discovery, research, development and commercialization of novel T-cell engaging bispecific antibodies targeting CD3 and tumor cell surface antigens for the treatment of canc...

Seattle Genetics (NASDAQ: SGEN ) and collaboration partner Astellas Pharma ( OTCPK:ALPMF ) announce Breakthrough Therapy status in the U.S. for antibody-drug conjugate PADCEV (enfortumab vedotin-ejfv), combined with Merck's (NYSE: MRK ) Keytruda (pembrolizumab), for the treatment of patien...

Astellas Pharma ( OTCPK:ALPMF ) and collaboration partner Pfizer (NYSE: PFE ) announce final overall survival (OS) data from a Phase 3 clinical trial, PROSPER , evaluating Xtandi (enzalutamide) plus androgen deprivation therapy (ADT) in men with non-metastatic castration-resistant prostat...

Seattle Genetics (NASDAQ: SGEN ) and collaboration partner Astellas Pharma ( OTCPK:ALPMF ) announce updated results from an open-label  Phase 1b/2 clinical trial evaluating the combination of antibody-drug conjugate (ADC) PADCEV (enfortumab vedotin-ejfv) and Merck's Keytruda (pembrol...